InsiderTrades.com logo
George M. Jenkins net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

George Jenkins Biography and Net Worth

Director of Palvella Therapeutics

From 1987 to 2005, Mr. Jenkins was a general partner of Apax Partners, a leading global private equity firm where he served as chief operating officer overseeing a multi-billion dollar venture capital and private equity investment portfolio. Since 2006, Mr. Jenkins has been an active private investor primarily funding technology-based start-ups. Mr. Jenkins has been or currently serves as a board member of numerous public and private companies, including SkinMedica (acquired by Allergan), Colorescience, Flower Orthopedics, Power Survey, Sunglass Hut, and Spyder Active Sports. Prior to joining Apax, Mr. Jenkins was a banker managing banking facilities in Europe. Mr. Jenkins earned a B.A. in Economics and Accounting from Lafayette College where he currently serves as a Trustee.

What is George M. Jenkins' net worth?

The estimated net worth of George M. Jenkins is at least $22.37 million as of September 14th, 2026. Jenkins owns 161,893 shares of Palvella Therapeutics stock worth more than $22,367,137 as of September 25th. This net worth approximation does not reflect any other assets that Jenkins may own. Learn More about George M. Jenkins' net worth.

How do I contact George M. Jenkins?

The corporate mailing address for Jenkins and other Palvella Therapeutics executives is 353 W. Lancaster Avenue, Suite 200, Wayne, PA, 19087. Palvella Therapeutics can also be reached via phone at (484) 253-1461 and via email at [email protected]. Learn More on George M. Jenkins' contact information.

Has George M. Jenkins been buying or selling shares of Palvella Therapeutics?

Over the course of the past ninety days, George M. Jenkins has sold $4,167,253.58 of Palvella Therapeutics stock. Most recently, George M. Jenkins sold 1,777 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $150.14, for a transaction totalling $266,798.78. Following the completion of the sale, the director now directly owns 160,116 shares of the company's stock, valued at $24,039,816.24. Learn More on George M. Jenkins' trading history.

Who are Palvella Therapeutics' active insiders?

Palvella Therapeutics' insider roster includes Kathleen Goin (COO), Elaine Heron (Director), George Jenkins (Director), and Christopher Kiritsy (Director). Learn More on Palvella Therapeutics' active insiders.

Are insiders buying or selling shares of Palvella Therapeutics?

In the last twelve months, Palvella Therapeutics insiders bought shares 2 times. They purchased a total of 6,400 shares worth more than $800,000.00. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 57,927 shares worth more than $7,716,071.58. The most recent insider tranaction occured on September, 16th when COO Kathleen Goin sold 4,302 shares worth more than $654,936.48. Insiders at Palvella Therapeutics own 17.2% of the company. Learn More about insider trades at Palvella Therapeutics.

Information on this page was last updated on 9/16/2026.

George M. Jenkins Insider Trading History at Palvella Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2026Sell1,777$150.14$266,798.78160,116View SEC Filing Icon  
9/14/2026Sell13,352$151.96$2,028,969.92161,893View SEC Filing Icon  
9/11/2026Sell12,371$151.28$1,871,484.88175,245View SEC Filing Icon  
2/27/2026Buy4,000$125.00$500,000.00187,171View SEC Filing Icon  
4/9/2025Buy2,500$20.13$50,325.00183,171View SEC Filing Icon  
12/18/2024Buy4,000$12.93$51,720.00180,671View SEC Filing Icon  
See Full Table

George M. Jenkins Buying and Selling Activity at Palvella Therapeutics

This chart shows George M. Jenkins's buying and selling at Palvella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palvella Therapeutics Company Overview

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $138.16
Low: $137.86
High: $147.44

50 Day Range

MA: $149.29
Low: $124.15
High: $158.13

2 Week Range

Now: $138.16
Low: $58.16
High: $161.38

Volume

193,330 shs

Average Volume

202,483 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A